Bromo-DragonFLY

Documented gangrene and limb amputation in healthy individuals; pre-existing vascular disease would catastrophically amplify this risk.

Raynaud's patients already experience episodic vasospasm; Bromo-DragonFLY's sustained alpha-1 adrenergic and 5-HT2B activation would produce dangerous additive vasoconstriction lasting days.

The compound's prolonged cardiovascular stress lasting 1-4 days poses extreme risk to individuals with coronary artery disease.

Predicted hERG inhibition combined with multi-day exposure creates sustained cardiac arrhythmia risk for individuals with congenital or acquired long QT syndrome.

Pre-existing epilepsy or seizure disorders are absolutely contraindicated given documented seizure induction in clinical cases.

Personal or family history of schizophrenia or other psychotic disorders represents an absolute contraindication.

Both manic and psychotic episodes are risks. The multi-day stimulant component and psychedelic effects could trigger mood destabilization.

While the compound is not hepatically metabolized, acute liver failure has been documented in overdose cases, suggesting a direct hepatotoxic mechanism at high tissue concentrations.

Absolute contraindication in pregnancy and lactation based on the compound's vasoconstrictive, sympathomimetic, and multi-day pharmacological profile.

All serotonergic medications are absolutely contraindicated due to MAO-A inhibition. The multi-day duration means the interaction risk window extends well beyond subjective effects.